Respiratorius AB (publ) (NGM: RESP)

Market Cap	19.88M
Revenue (ttm)	n/a
Net Income (ttm)	-8.15M
Shares Out	5.10M
EPS (ttm)	-1.79
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,942
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	3.660 - 33.000
Beta	1.67
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 11, 2025

About Respiratorius AB

Respiratorius AB (publ), a research company, develops drug candidates for the treatment of cancer, chronic obstructive pulmonary disease (COPD), and asthma. The company’s products under development include VAL001, which has completed Phase III clinical trials for the treatment of diffuse large B-cell lymphoma; and VAL001, a product candidate that is in preclinical phase for the treatment of relapsing diffuse large B-cell lymphoma. Respiratorius AB (publ) was incorporated in 1998 and is based in Lund, Sweden.

• Industry: Other
• Founded: 1998
• Employees: 1
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: RESP